BISA virtually attended the World Consensus Conference on BIA-ALCL to get the update on breast implant associated cancers and how to assist the public.

BISA delves into the agency statements on the recently published recommendations about the removal of textured implants in asymptomatic patients.

The American College of Radiology published updated guidance for patients who have symptoms of BIA-ALCL.

This month, the British Medical Journal (BMJ) published a life-saving article for patients and doctors on Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA ALCL), the most common cancer caused by breast implants. 

BISA leadership, in partnership with the American Society of Plastic Surgeons (ASPS), attended a highly successful “Hill Day” on June 14, 2023, in Washington, D.C., aimed at educating members of Congress on the alarming trends involving the most common cancer caused by breast implants called Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).

Breast Implant Associated Lymphoma (BIA-ALCL) is a type of non-Hodgkin's lymphoma, a cancer of the immune system. Accumulating evidence suggests that BIA-ALCL may be a common—not rare—risk from exposure to Allergan Biocell® breast implants.

Maria Gmitro of Breast Implant Safety Alliance (BISA) addresses breast implant related illness and cancers, BIA-ALCL, and BIA-SCC with a focus on informed consent and her personal experience with breast implants, advocacy and the FDA.